

### AMENDMENTS TO THE CLAIMS

---

Claims 1-4 (Withdrawn)

Claims 5-7 (Canceled)

8. (Currently Amended) A ~~non-human~~ transgenic ~~animal~~ mouse comprising a homozygous disruption in a NOR1 ~~gene~~ wherein the transgenic mouse exhibits, relative to a wild-type mouse, impaired balance or motor coordination, or an increased or enhanced pain response threshold.

9. (Currently Amended) A cell derived from the ~~non-human~~ transgenic ~~animal~~ mouse of claim 8.

10. (Currently Amended) A method of producing a transgenic mouse comprising a homozygous disruption in the NOR1 ~~gene~~, the method comprising:

Q3 (a) ~~introducing the targeting construct of claim 1 into a cell~~ introducing a construct that targets NOR1 into a mouse embryonic stem cell;

(b) introducing the embryonic stem cell into a blastocyst;

(c) implanting the resulting blastocyst into a pseudopregnant mouse, wherein said pseudopregnant mouse gives birth to a chimeric mouse; and

(d) breeding the chimeric mouse to produce the transgenic mouse wherein the transgenic mouse exhibits, relative to a wild-type mouse, impaired balance or motor coordination, or an increased or enhanced pain response threshold.

Claims 11-13 (Withdrawn)

Claims 14-15 (Canceled)

Claims 16-17 (Withdrawn)

Claims 18-19 (Canceled)

Claims 20-26 (Withdrawn)

27. (New) The transgenic mouse of claim 8, wherein the impaired balance or motor coordination is characterized by the mouse falling at lower average speed during a rotarod test.

Application No. 10/005,169  
Deltagen Docket No. R-687

28. (New) The transgenic mouse of claim 8, wherein the increased or enhanced pain response threshold is characterized by an increased response latency during a hot plate test.

---